April 8, 2015
"Diagnostic patenting since Myriad: an update" by Patrick R. H. Waller and Daniel W. Young
Stakeholders shouldn’t conclude that nothing is patent eligible in the diagnostic space. Read more
"CRISPR/Cas-9: An Exciting Addition to Genomic Editing" by Patricia Granahan and Chelsea A. Loughran
This article provides an in-depth review of (1) the science behind this new technology, (2) several of the research groups responsible for the promising applications for this technology, and (3) the related and evolving intellectual property (IP) landscape. Read more
"The New World of Diagnostic Testing Post-Myriad" by Patrick R. H. Waller and Daniel W. Young
Claims to isolated DNA segments that exist in nature are not patent eligible, but claims to certain synthetic molecules relevant to genetic testing—as well as certain method-of-use patents—likely remain patent eligible. Read more
To view older publications, go to Publications.